Mezigdomide
Highest phase reached
Phase 3
Drug type
Small molecule
- Listing at source
- Listed
- Highest phase reached
- Phase 3
- Drug type
- Small molecule
- Drug name
- Mezigdomide
- Molecular weight
- 567.62
- Structure (SMILES)
- N#Cc1ccc(N2CCN(Cc3ccc(COc4cccc5c4CN([C@H]4CCC(=O)NC4=O)C5=O)cc3)CC2)c(F)c1
- cc 92480
- Cc-92480
- CC-92480
- cc92480
- CC92480
- cpd 3 cc 92480
- CPD. 3(CC-92480)
- mezigdomide
- Mezigdomide
- MEZIGDOMIDE
- MEZIGDOMIDE (CC-92480)
- mezigdomide [INN]
- MEZIGDOMIDE [USAN]
- Mezigdomide [WHO-DD]
- mezigdomide cc 92480
- mezigdomide inn
- mezigdomide usan
- mezigdomide who dd
- CAS registry numbers
- 2259648-80-9
- ChEMBL ID
- CHEMBL4648616
- InChIKey
- YTINZZFBHWSAGL-NDEPHWFRSA-N
- PubChem compound IDs
- 137379043
- FDA ingredient codes (UNII)
- LA88IH4O02
- Patents
- 0
- Designations
- 1
- First in class
- No
- Fast track
- No
- Breakthrough designation
- No
- Orphan designation
- No
- Priority review
- No
- Orphan exclusivity
- No
- Accelerated approval
- No
- Pharmacology name
- mezigdomide
- Type
- Synthetic organic
- Drug name stem
- -domide
Mechanisms of action
- Action
- Binding
- Action type
- Binding
- Target
- cereblon
- Gene symbol
- CRBN
- Protein identifier
- Q96SW2
- Median affinity
- 7.52
- Affinity units
- pIC50
- Condition
- Multiple Myeloma
- Highest recorded phase
- 3
- Condition identifier
- EFO:0001378
- Subject identifier
- D009101
- Condition
- Liver Diseases
- Highest recorded phase
- 1
- Condition identifier
- EFO:0001421
- Subject identifier
- D008107
- Condition
- Kidney Diseases
- Highest recorded phase
- 1
- Condition identifier
- EFO:0003086
- Subject identifier
- D007674
- Condition identifier
- EFO_0001378
- Highest recorded phase
- 3
- Condition identifier
- EFO_0001421
- Highest recorded phase
- 1
- Condition identifier
- EFO_0003086
- Highest recorded phase
- 1
- Condition identifier
- MONDO_0009693
- Highest recorded phase
- 3
- Condition identifier
- MONDO_0010643
- Highest recorded phase
- 1
- Condition identifier
- MONDO_0018874
- Highest recorded phase
- 1
Reported adverse events
- Event
- plasma cell myeloma refractory
- Reports
- 1
- Reporting signal score
- 10.3391
- NCT02343042
- NCT03374085
- NCT03989414
- NCT05372354
- NCT05519085
- NCT05552976
- NCT05981209
- NCT06048250
- NCT06050512
- NCT06121843
- NCT06163898
- NCT05707390
- NCT06318676
- Hydrogen bond acceptors
- 7
- Hydrogen bond donors
- 1
- Polar surface area
- 105.98
- Calculated partition coefficient (ALogP)
- 3.36
- Calculated partition coefficient (XLogP)
- 2.9
- Prodrug
- No
- Chirality
- Single enantiomer
- Inorganic
- No
- Rule-of-five violations
- 1
- Rotatable bonds
- 7
- Heavy atoms
- 42
- Molecular formula
- C32H30FN5O4
- Monoisotopic mass
- 567.22818262
- Natural product
- No
- Recorded assays
- 94
- Active assays
- 5
Active assay types
- Confirmatory
Solubility
- Median
- 90
- Mean
- 90
- Minimum
- 90
- Maximum
- 90
- Unit
- ug/mL
- Assays
- 1
- Standard deviation
- 0
- Summary method
- median
- Censored results excluded
- 0
- Other units excluded
- 0
- Unknown units excluded
- 0
Measurement types
- Solubility
Oral bioavailability
- Median
- 38
- Mean
- 38
- Minimum
- 38
- Maximum
- 38
- Unit
- %
- Assays
- 1
- Standard deviation
- 0
- Summary method
- median
- Censored results excluded
- 0
- Other units excluded
- 0
- Unknown units excluded
- 0
Measurement types
- F
Related records
Trials (28)
- A Safety, PK and Efficacy Study of CC-92480 Monotherapy and in Combination With Dexamethasone in Subjects With Relapsed and Refractory Multiple Myeloma (RRMM)
- A Study of an MMSET Inhibitor in Patients With Relapsed and Refractory Multiple Myeloma
- A Study of Mezigdomide in Healthy Participants and Participants With Hepatic Impairment
- A Study of Revumenib and Mezigdomide in People With Leukemia
- A Study of Teclistamab and Mezigdomide in People With Multiple Myeloma
- A Study to Assess Change in Disease Activity and Adverse Events (AE)s in Adult Participants With Multiple Myeloma Receiving T Cell Engaging Bi/Tri-specific Antibodies Intravenously (IV)/Subcutaneously (SC) Alone or in Combinations
- A Study to Assess Safety, Tolerability, and Pharmacokinetics of CC-92480 Formulations in Healthy Adult Participants
- A Study to Assess the Drug Levels of CC-92480 After Coadministration With Rifampin and Itraconazole, and the Drug Levels of Digoxin and Rosuvastatin After Coadministration With CC-92480 in Healthy Participants
- A Study to Determine the Recommended Dose and Regimen and to Evaluate the Safety and Preliminary Efficacy of CC-92480 in Combination With Standard Treatments in Participants With Relapsed or Refractory Multiple Myeloma (RRMM) and Newly Diagnosed Multiple Myeloma (NDMM)
- A Study to Determine the Recommended Dose and Schedule, and Evaluate the Safety and Preliminary Efficacy of Mezigdomide in Combination With Elranatamab in Participants With Relapsed and/or Refractory Multiple Myeloma
- A Study to Evaluate Alnuctamab in Combination With Mezigdomide in Participants With Relapsed and/or Refractory Multiple Myeloma
- A Study to Evaluate Mezigdomide in Combination With Carfilzomib and Dexamethasone (MeziKD) Versus Carfilzomib and Dexamethasone (Kd) in Participants With Relapsed or Refractory Multiple Myeloma (SUCCESSOR-2)
- A Study to Evaluate Mezigdomide, Bortezomib and Dexamethasone (MEZIVd) Versus Pomalidomide, Bortezomib and Dexamethasone (PVd) in Participants With Relapsed or Refractory Multiple Myeloma (RRMM)
- A Study to Evaluate Safety, Drug Levels and Effectiveness of CC-92480 (BMS-986348) in Combination With Other Treatments in Participants With Relapsed or Refractory Multiple Myeloma
- A Study to Evaluate the Drug Levels of Mezigdomide in Adult Participants With Renal Impairment
- A Study to Evaluate the Metabolism and Excretion of [14C]-CC-92480 in Healthy Male Participants
- A Study to Evaluate the Safety, Effectiveness and Tolerable Dose of Arlocabtagene Autoleucel (BMS-986393) in Novel Combinations in Participants With Relapsed and/or Refractory Multiple Myeloma
- Elotuzumab, CC-92480, and Dexamethasone for the Treatment of Relapsed or Refractory Myeloma After CD38- and BCMA-Targeted Therapies
- Expanded Access for Mezigdomide
- Mezigdomide (CC-92480) Post Idecabtagene Vicleucel in Treating Patients With Relapsed Multiple Myeloma
In development for (3)
- Kidney disorder Phase 1
- Liver disorder Phase 1
- Plasma cell myeloma Phase 3